To include your compound in the COVID-19 Resource Center, submit it here.

TXA127: Phase I started

Tarix began an open-label, U.S. Phase I trial to evaluate daily 300

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE